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Strengths and limitations of this study
 ► This pilot study comprehensively tests the design of 
a randomised controlled trial for the primary preven-
tion of atopic eczema using a mixture of quantitative 
and qualitative methods.
 ► In addition, various mechanistic measurements will 
further our understanding of the mechanisms by 
which water softeners might prevent atopic eczema.
 ► This study is being performed in two centres to gain 
a wider understanding of potential barriers and facil-
itators to recruitment and retention in a multicentre 
definitive trial.
 ► The study is outcome assessor blinded as partici-
pant blinding is not possible to achieve.
 ► Follow-up is only for 6 months and so may not pro-
vide full information on postrandomisation losses to 
follow-up that could occur in a future definitive trial 
with a longer duration of follow-up.
ABSTRACT
Introduction Atopic eczema affects 20% of UK children, 
and environmental factors are important in its aetiology. 
Several observational studies suggest an increased risk 
of atopic eczema in children living in hard water areas. 
The Softened Water for Eczema Prevention pilot trial 
tests the feasibility of installing domestic ion-exchange 
water softeners around the time of birth to reduce the 
risk of atopic eczema in children with a family history of 
atopy. A further aim is to explore the pathophysiological 
mechanisms for this in an embedded mechanistic study.
Methods and analysis Multicentre parallel group 
assessor-blinded randomised controlled pilot trial. 
Participants are newborn babies (n=80) living in a hard 
water (>250 mg/L calcium carbonate) area at risk of 
developing atopic eczema because of a family history of 
atopy. Participants will be randomised prior to birth in a 
1:1 ratio. The intervention group will have an ion-exchange 
water softener installed prior to birth. The control group will 
receive their usual domestic hard water supply. Follow-up 
will be until 6 months of age. Data will be collected at birth 
(baseline), 1, 3 and 6 months of age. The main outcome 
is the proportion of eligible families screened who are 
willing and able to be randomised. Several secondary 
feasibility and clinical endpoints will also be evaluated, 
alongside mechanistic outcomes. Data will be analysed 
on an intention-to-treat basis. There will be no hypothesis 
testing for the clinical outcomes. Study acceptability will be 
evaluated through semistructured interviews.
Ethics and dissemination This study has been 
reviewed and given a favourable opinion by the North 
West–Liverpool East Research Ethics Committee (Ref: 17/
NW/0661). The results of the study will be reported at 
international conferences and in peer-reviewed scientific 
journals. We will send participating families a summary of 
the pilot trial results.
Trial registration number NCT03270566.
InTRoduCTIon
Background & Rationale
Atopic eczema (synonym atopic derma-
titis, hereinafter referred to as ‘eczema’) 
is a common inflammatory skin condition 
affecting around 20% of UK children.1 It is 
associated with significant morbidity and 
affects health-related quality of life. The cause 
of eczema is not fully understood. It is likely 
to be multifactorial, and several genetic and 
environmental factors have been identified.2 
No primary prevention strategy has been 
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established.3 However, several approaches have been 
proposed such as probiotics during pregnancy, dietary 
supplementation, house dust mite avoidance, intensive 
emollient use and domestic water softening.4
Relationship between hard water and atopic eczema
Hard water is the result of dissolved minerals, mainly 
calcium carbonate and magnesium carbonate, from the 
percolation of water through rock in the environment. 
England, especially in the south, has very hard (>250 mg/L 
calcium carbonate) domestic water. A cross-sectional study 
conducted in the 1990s found that primary school-age 
children living in hard water areas had an increased risk 
of eczema compared with children living in softer water 
areas around Nottingham, UK.5 Two further cross-sec-
tional studies among schoolchildren conducted in Japan 
and Spain confirmed this association.6 7 Subsequently, a 
cross-sectional analysis from a cohort study among over 
1300 infants in England and Wales has also confirmed 
this relationship in early life, even after adjusting for likely 
confounders.8 The same study suggested a possible interac-
tion with loss-of-function mutations in the skin barrier gene, 
filaggrin (FLG). Most recently, a large study from a Danish 
birth cohort found a 5% increase in prevalence of eczema 
within the first 18 months of life for each 5 unit increase in 
domestic water hardness (equivalent to 89.2 mg/L calcium 
carbonate)9 over a range of 6.60–35.90 German degrees of 
hardness (118–641 mg/L calcium carbonate).10
Potential mechanisms for hard water causing atopic eczema
Several potential mechanisms have been proposed for 
the way in which hard water may lead to eczema develop-
ment: increased deposition of detergents such as sodium 
lauryl sulfate (SLS) on the skin, altered calcium signalling 
in the epidermis and a rise in skin surface pH, resulting 
in increased protease activity, could all have a detrimental 
effect on skin barrier function.8 Experimental work has 
demonstrated an increased deposition of SLS in skin 
washed with hard water versus softened water.11 In animal 
studies using a hairless mouse model, low extracellular 
concentrations of calcium ions in the upper epidermis 
led to exocytosis of lamellar bodies, required for skin 
barrier repair, independent of skin barrier disruption.12
Eczema is associated with a preponderance of Staphylo-
coccus aureus and a reduction in microbial diversity.13 Recent 
work has identified a synergistic relationship between the 
human cathelicidin-related antimicrobial peptide LL-37 
and antimicrobial peptides produced by coagulase negative 
staphylococcal species that selectively kill S. aureus.14 Human 
LL-37 activity against some bacterial species is decreased by 
the presence of calcium, but not magnesium, ions.15
Trials of water softeners in atopic eczema
The multicentre Softened Water Eczema Trial (SWET), 
completed in 2011, examined the role of water softeners 
in treating children with established, moderate to severe 
eczema and found no overall benefit in terms of eczema 
severity reduction.16 However, the factors that drive the 
development of eczema may not be the same as those 
that determine disease exacerbations and severity and the 
negative result in the SWET does therefore not exclude 
a role for water softeners in prevention trials. Early life 
is likely to be an important time in the development of 
eczema, particularly as most eczema develops before 
2 years of age. Early interactions between genes and 
the environment may be crucial in instigating the cycle 
of inflammation and skin barrier dysfunction seen in 
eczema. Indeed, skin barrier dysfunction at just 1 week of 
age, as measured by transepidermal water loss (TEWL), 
is a predictor of subsequent eczema risk.17 A small pilot 
randomised controlled double-blind cross-over trial of 
12 patients aged 3–6 years with mild to moderate eczema 
compared ultrapure soft water with tap water. After 6 
weeks, no statistically significant differences in Eczema 
Area and Severity Index (EASI) or TEWL were observed 
between the groups, although there was a statistically 
significant improvement in pruritus as measured by visual 
analogue score (−2.10, 95% CI −4.14 to 0.063).18 To date, 
there are no published studies examining the role of 
water softeners in the prevention of eczema.19
Rationale
The overall rationale is that by installing a domestic 
water softener around the time of birth, the infant will 
be exposed to softened water rather than hard water for 
bathing and that this will be less irritating to the skin than 
hard water and so associated with a lower risk of eczema 
development.
This pilot trial builds on the experience gained from the 
National Institute for Health Research (NIHR)-funded 
SWET16 and a trial of emollients in early life (Barrier 
Enhancement for Eczema Prevention, BEEP),20 both of 
which were coordinated by KST and JRC, our collabora-
tors on this trial, who are based at the Centre of Evidence 
Based Dermatology in Nottingham. This is a pilot trial, as 
defined by the UK NIHR in that it is a ‘version of the main 
study that is run in miniature to test whether the compo-
nents of the main study can all work together.’21 This pilot 
trial will therefore not definitively answer the question 
of whether installation of a domestic water softener will 
prevent eczema. The rationale for performing this pilot 
study is that a definitive trial on eczema prevention using 
domestic water softening devices would require a much 
larger number of participants and so prior to embarking 
on a larger multicentre trial it will be important to deter-
mine whether the planned trial recruitment and assess-
ment procedures are possible and workable, or whether 
they require adapting or changing.22
Trial objectives
The aim of this pilot trial is to determine the feasibility 
of undertaking a large-scale definitive trial to determine 
whether installation of domestic ion-exchange water 
softeners around the time of birth reduces the risk of 
high-risk children developing eczema. A further aim is to 
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Figure 1 Study flow chart.
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Table 1 Inclusion and exclusion criteria
Inclusion criteria
Antenatal maternal
1 History of doctor-diagnosed atopy (atopic eczema, asthma or hay fever) in the woman, her partner or other 
child the couple have parented.
2 Woman aged 18 years or older.
3 Woman able to understand English.
4 Lives in a hard water area (>250 mg/L calcium carbonate).
5 Lives in a property suitable to have a water softener fitted.
6 If in a rented property—agrees to seek consent of landlord for fitting of water softener device.
7 Agrees to have water softener±additional tap for drinking water fitted at home.
8 Agrees to researchers accessing pregnancy and pregnancy outcome data for the mother and child.
9 Able and willing to give informed consent.
Postnatal maternal
10 Maternal consent for her neonate to participate in the study.
Exclusion criteria
11 Preterm birth (defined as birth prior to 37 weeks’ gestation).
12 Significant inflammatory skin disease at birth not including seborrheic dermatitis (‘cradle cap’).
13 Sibling (including twin) previously randomised to this trial. If multiple birth, the first child will be randomised 
into the trial.
14 Any immunodeficiency disorder or severe genetic skin disorder.
15 Child has any other serious health issue which, at parent or investigator discretion, would make it difficult for 
the family to take part in the trial.
16 Planned stays away from home for a continuous period of more than 2 weeks or a total of 1 month out of the 
6-month follow-up period.
17 Water softening or filtration device already installed.
18 Concurrent enrolment in any other skin-related intervention study.
19 Other medical condition that in the opinion of the chief investigator could interfere with the conduct of the 
trial.
explore the pathophysiological mechanisms for this in an 
embedded mechanistic study.
METhodS And AnAlySIS
Trial design
This is a multicentre parallel group assessor-blinded 
randomised controlled pilot trial of an ion-exchange 
water softener for the prevention of eczema in neonates at 
high risk of developing eczema, with an embedded mech-
anistic study. Eighty newborn infants will be enrolled into 
the trial for a period of 6 months. The end of study is 
defined as the final assessment visit of the last participant 
to enter the trial. Recruitment commenced in February 
2018 and is due to end in autumn 2019.
Pregnant women will be randomised prior to delivery 
to one of two groups in a 1:1 ratio:
 ► Control group: usual domestic hard water supply.
 ► Intervention group: softened domestic water through 
installation of an ion-exchange water softener.
The study design is summarised as a flow chart in 
figure 1.
Patient involvement
Patients were involved in the design of this study. 
Members of the Patient Panel at the Centre of Evidence-
Based Dermatology reviewed the participant material and 
provided feedback on the online questionnaires. During 
the trial, a parent of a child with eczema will join the inde-
pendent trial steering committee. Once the trial has been 
published, participants will be sent details of the results in 
a study newsletter suitable for a non-specialist audience.
Trial population
The study will recruit pregnant women living in hard 
water areas who will be identified from antenatal services 
at local National Health Service Trust sites. Women will 
be approached at the 20-week anomaly scan and asked 
if they would be interested in participating. We will also 
publicise the study through posters and by making clin-
ical midwifery teams aware of the study. Full inclusion and 
exclusion criteria are given in table 1.
Intervention
A domestic ion-exchange water softener will be 
installed in the homes of participants randomised to 
Protected by copyright.
 o
n
 August 21, 2019 at G
reenfield M
edical Library Periodicals.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027168 on 20 August 2019. Downloaded from 
5Jabbar-Lopez ZK, et al. BMJ Open 2019;9:e027168. doi:10.1136/bmjopen-2018-027168
Open access
the intervention group after enrolment and before the 
child’s birth. Ion-exchange water softeners exchange 
calcium and magnesium, among other divalent cations, 
for monovalent sodium cations, typically reducing down-
stream water hardness to close to zero. The sodium ions 
come from common salt which needs to be topped up 
every 3–4 weeks. The water softeners to be used in this 
trial will be supplied and funded by Harvey Water Soft-
eners, Woking, UK. Standard procedure will be to soften 
all water in the home except the drinking water tap, as 
the water softening process exchanges calcium with 
sodium ions and will therefore increase the water sodium 
concentration, making the water unsuitable for drinking 
purposes. Unsoftened mains drinking water will be deliv-
ered through the existing kitchen tap wherever possible, 
or otherwise through an extra (faucet-style) tap installed 
at the side of the kitchen sink. At the end of the study, 
all participants will be given the option to purchase the 
water softener from Harvey Water Softeners at a reduced 
price of £399.00 inclusive of value-added tax, installation 
and warranty; this is approximately a quarter of the full 
retail price of £1678.80. Alternatively, it will be removed.
Potential risks
This is a low-risk trial as the intervention involves a 
commercially available ion-exchange water softener that 
has no known clinical side effects. There is a potential, 
but low risk, of damage to participants’ properties during 
installation of the water softening unit. However, these 
will be installed by a qualified water engineer according 
to the Code of Practice produced by British Water and 
in accordance with the recommendations of the Water 
Regulations Advisory Service.
Concomitant medications and skincare
No restrictions will be placed on the use of concomi-
tant treatment a child might receive. All concomitant 
medications will be recorded at baseline and updated at 
follow-up visits. Given the lack of a consistent approach to 
neonatal skincare, and the possible interaction between 
some wash products and hard water, we will not provide 
specific skincare advice to participants. However, data on 
such use will be sought from parents via monthly online 
questionnaires.
Coenrolment guidelines
To avoid potentially confounding issues, neonates should 
not be recruited into other prevention of eczema or 
allergy intervention trials.
Participant compliance
Compliance with treatment does not represent a large 
problem for this trial as long as the participants are not 
absent from home for long periods of time and remember 
to replenish the salt. Reminders about salt replenishment 
will be sent. To check that the units are working correctly, 
participants will be asked to send weekly water samples 
to Harvey Water Softeners using prepaid envelopes. Any 
samples with a reading of >20 mg/L calcium carbonate 
will be referred back to the engineer for investigation. 
If participants move home during the trial, attempts will 
be made to reinstall the device in the new property. It is 
anticipated that loss to follow-up will be <15%.
Primary outcome
Proportion of eligible families screened who are willing 
and able to be randomised. This is key to the determina-
tion of the likely success of a future, large-scale definitive 
randomised controlled trial (RCT).
Secondary feasibility outcomes
The secondary objectives are designed to further facil-
itate the design of a larger, definitive multicentre RCT. 
Namely, to determine the proportion of:
1. Pregnant women approached who agree to be 
screened.
2. Families eligible on screening that cannot have a wa-
ter softener installed (eg, due to landlord or local au-
thority refusal, technical (plumbing) reasons).
3. Families randomised that withdraw due to infant 
ineligibility.
4. Families in intervention arm who found the interven-
tion acceptable.
5. Participants in control arm who become exposed to 
softened water (eg, by moving to a new home in a soft 
water area, or moving to a home with an active water 
softener installed, before the end of follow-up).
6. Participants that have the water softening unit re-
moved or disabled prior to end of follow-up.
7. Participants with visible eczema status (yes/no) re-
corded at each time point: baseline, 4 weeks, 3 and 
6 months.
8. Water samples with hardness >20 mg/L calcium car-
bonate in the intervention arm.
9. Participants who withdraw from the trial prior to end 
of follow-up.
10. Median number of nights spent away from the partic-
ipant’s main home during follow-up.
11. Clinical outcome assessments that have remained 
blinded at 4 weeks, 3 and 6 months.
Secondary clinical outcomes
1. Proportion with patient-reported, doctor-diagnosed 
atopic eczema by 6 months of age.
2. Proportion with visible eczema according to the UK di-
agnostic criteria-based photographic protocol.23
3. Severity of eczema (if present) using EASI.
4. Patient-reported eczema symptoms (Patient-Oriented 
Eczema Measure) score.
5. Time to onset of patient-reported doctor-diagnosed 
eczema.
Additional mechanistic outcomes
The following will be assessed as change from baseline 
until follow-up at 6 months in the intervention compared 
with the control group:
1. TEWL.
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2. Cutaneous cytokine profiles (eg, interleukin-1 (IL-1) 
levels).
3. Natural moisturising factor levels.
4. Shannon Diversity Index and other skin and upper re-
spiratory microbiota parameters.
5. Median domestic water hardness level (calcium car-
bonate concentration).
6. Skin surface hydration.
Adverse events
This trial involves use of a commonly available domestic 
water softening unit with provision for separate mains 
drinking water during the time when the water softening 
unit is installed. Accordingly, we do not anticipate any 
adverse events or adverse reactions related to the trial 
intervention. A contact number for the service depart-
ment at Harvey Water Softeners will be provided and 
an engineer will be sent to resolve the issue, if needed. 
Details of technical issues reported to the service depart-
ment will be reported to the study principal investigators. 
Events of particular relevance such as plumbing difficul-
ties, floods or difficulties with the units will be logged and 
reported to the Research Ethics Committee and relevant 
Research and Development departments annually.
Sample size
This is a pilot study and therefore not powered to estab-
lish the efficacy of the intervention. A total of 80 families 
(40 per group) is judged to provide a sufficiently precise 
(within 10 percentage points for a 95% CI) estimate of the 
proportion of families who are willing to be randomised 
and who will go on to complete the trial.
Findings from the Enquiring About Tolerance (EAT) 
study8 and the BEEP feasibility study24 allowed us to make 
a conservative estimate that approximately 70% of fami-
lies screened will have a history of atopy that predisposes 
to a high risk of eczema in their offspring. Of these, 
40%–60% would be expected to be willing and able to 
participate. Home factors also need to be considered: 
in SWET, 27% of eligible families could not participate 
because their home was not suitable for installation.16
Informed consent
Written informed antenatal consent will be obtained at 
the enrolment visit from the mother. The consent form 
will be signed and dated before entering the trial and 
participants are reminded that they may withdraw from 
the trial at any time. Mothers will be reconsented post-
natally to ensure they agree to their child taking part in 
the study.
Randomisation and blinding
Participants will be randomised antenatally at the time of 
the engineer home visit to receive either a water softener 
or their usual water supply, once:
 ► Antenatal eligibility criteria have been fulfilled.
 ► Fully informed written consent has been obtained.
 ► The engineer is satisfied that the softener can be 
installed.
Participants will be randomised in a 1:1 ratio to one 
of the two treatment arms based on a computer-gen-
erated code. The randomisation result will be relayed 
to the installation engineer by telephone as either an 
‘INSTALL’ or ‘DO NOT INSTALL’ instruction. The 
randomisation service will be provided by researchers 
at King’s College London who are not involved in the 
study, via telephone.
Experience from the SWET has shown that the effects 
of a functional water softener are too noticeable to 
allow participants to be blinded.16 Skin examinations 
and measurements will be performed by research team 
members who will be blinded to treatment allocation. 
Participants will be encouraged not to disclose allocation. 
Results will be analysed based on treatment code, using a 
statistical analysis plan (SAP) finalised prior to database 
lock and any data analysis. Only after the analyses are 
completed will the actual treatment arms corresponding 
to treatment codes be revealed. Study team members 
in direct contact with study participants will be trained 
in the study protocol and importance of demonstrating 
equipoise.
Visit schedule and study procedures
The schedule for assessments during the study is shown 
in table 2.
Enrolment visit (up until 36 weeks’ gestation)
 ► Confirm eligibility (see table 1).
 ► Answer questions about study.
 ► Written consent is taken.
 ► Antenatal history (including antibiotic exposure, 
probiotic and omega 3 use), family medical history 
and environment questionnaire.
 ► Arrange water softener installation.
The enrolment visit may occur at the same time as the 
screening visit, if preferred by the participant and deemed 
appropriate by the investigator.
Water softener engineer home visit (up until 40 weeks’ gestation)
 ► Assessment by the engineer to check the home’s suit-
ability for water softener installation.
 ► If home eligible, the engineer will telephone a given 
number at King’s College London to determine the 
randomisation group.
 ► Install water softener and provide water sample mate-
rials if randomised to the intervention arm.
Baseline visit (on postnatal ward or within 1 week of birth)
 ► Confirm infant eligibility criteria.
 ► Postnatal written consent.
 ► Skin examination.
 ► Infant skincare questions.
 ► Record concomitant infant medications including 
systemic antibiotic use.
 ► Systemic antibiotic use in mother during pregnancy, 
including prophylactic antibiotic use during delivery.
 ► Infant comorbidities.
 ► Topical medication use in infant.
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Table 2 Schedule of study assessments and procedures
Screening* Enrolment*
Home screen 
and installation Birth
Baseline 
(±1 week)
4 weeks 
(±1 week)
3 months 
(±2 weeks)
6 months 
(±2 weeks)
Confirm eligibility X X X
Verbal consent to collect 
contact details and 
access antenatal records
X
Written informed consent X X
Demographic data X X
Engineer home 
assessment
X
Install water softener X
Randomisation X
Visible eczema status X X X
Blinded eczema severity 
assessment (EASI)
X X X
DNA collection from 
buccal swab
X
Antenatal factors 
questionnaire
X
Acceptability and 
feedback questionnaire
X
Invite to participate in 
semistructured interview 
about study
X
Collection of skin and 
nasal microbiome swabs
X X X X
TEWL measurement‡ X X X X
Cutaneous tape 
stripping‡
X X X X
Skin pH measurement‡ X X X X
ATR-FTIR measurement‡ X X X X
Skin surface hydration‡ X X X X
Monthly infant skin and 
health† questionnaire, 
including Patient-Oriented 
Eczema Measure (POEM) 
score
From 4 weeks to 6 months of age
Weekly water samples (in 
intervention arm)
From installation to 6 months of age
*Screening and enrolment may occur at the same visit if participant prefers and if investigator agrees.
†Any other concomitant illnesses that develop during the study including episodes of respiratory, gastrointestinal and other acute 
illnesses.
‡At Guy’s and St Thomas’ Hospital site only.
ATR-FTIR, attenuated total reflectance Fourier transform infrared; EASI, Eczema Area and Severity Index; POEM, Patient-Oriented 
Eczema Measure; TEWL, transepidermal water loss.
 ► Delivery questions.
 ► Pregnancy outcomes and birth details.
 ► Additional mechanistic assessments (procedures 
marked ‡ will be performed only at the Guy’s and St 
Thomas’ Hospital site):
 – Tape stripping (forearm).
 – TEWL measurement (forearm)‡.
 – Attenuated total reflectance Fourier transform 
infrared (ATR-FTIR) spectroscopy measurement 
(forearm)‡.
 – Skin pH measurement (forearm)‡.
 – Skin surface hydration (forearm) ‡.
 – Microbiome swabs from skin (antecubital fossa and 
cheek) and nares.
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Four-week visit (±1 week)
 ► As per baseline, plus optional buccal swab for DNA for 
FLG mutation analyses.
Three-month visit (±2 weeks)
 ► As per baseline, plus optional buccal swab for DNA for 
FLG mutation analyses (if unable to collect at 4-week 
visit).
Six-month visit (±2 weeks)
 ► As per baseline, plus:
 ► Acceptability questionnaire.
 ► Optional buccal swab for DNA for FLG mutation anal-
yses (if unable to collect at 3-month visit).
 ► Arrange date for removal of water softener within 
1 month if not planning to purchase (intervention 
group) or installation of water softener for 6 months 
period, if desired, in control arm.
 ► Invite to participate in semistructured qualitative 
interview about study (via telephone or in person) 
and seek verbal consent for this.
Monthly email messages (intervention group)
 ► Remind participants to complete questionnaires.
 ► Remind participants’ parents to refill the unit with 
salt.
 ► Invite to contact Harvey Water Softeners for any issues 
with water softener.
Monthly email messages (control group)
 ► Remind participants to complete questionnaires.
Monthly electronic questionnaires
A secure web-based questionnaire link using the Snap 
Surveys platform will be emailed to participants’ parents 
monthly to determine whether the child has received a 
diagnosis of eczema from a healthcare professional and 
to check current skincare and hygiene, and confirm 
residence/time away from main residence and infant 
general health. A paper copy of the questionnaire can be 
posted to participants if they prefer or if they do not have 
internet access.
At the end of the study, that is, 6-month visit, a date 
will be arranged for removal of the water softener within 
1 month if the participating family does not want to 
purchase the device (intervention group). Control arm 
participants can purchase the same water softener at the 
end of the study. Participants will also be invited to partic-
ipate in a semistructured qualitative interview about the 
study.
Embedded mechanistic substudy
The embedded mechanistic substudy will help elucidate 
the mechanisms by which softened water might affect 
skin barrier function and therefore eczema risk. It will 
also provide more general insights into the pathogenesis 
of eczema in young infants with resulting opportunities 
for hypothesis generation.
ATR-FTIR spectroscopy measurements will be 
performed using the Agilent 4300 ATR-FTIR device 
(Agilent Technologies, USA) to measure the deposition 
of detergents, such as SLS, on the skin surface.25
TEWL provides a standardised measure of skin barrier 
dysfunction26 and there is evidence to suggest that 
elevated TEWL in neonates is predictive of subsequent 
eczema.17 27 We will use the AquaFlux AF200 condensing 
chamber probe (Biox Systems, London, UK) to measure 
TEWL. Epidermal stratum corneum hydration will be 
measured using a CM 825 Corneometer (Courage and 
Khazaka, Cologne, Germany).
Skin surface pH has an important role in the regula-
tion of epidermal and microbial cellular process and will 
be measured using a PH905 Skin-Surface-pH probe fitted 
with a Mettler and Toledo flat surface electrode (Courage 
and Khazaka).28
Skin protein samples will be collected from the skin by 
applying and removing eight consecutive D-Squame cuta-
neous stripping discs (CuDerm, Dallas, USA). Samples 
will be collected to perform the protein and cytokine 
analyses, such as IL-1ɑ levels.29
The FLG gene encodes profilaggrin protein and its 
subsequent breakdown products are key to normal barrier 
function of the skin. Loss-of-function sequence variants 
in FLG are associated with an increased risk of eczema 
(Palmer, 2006). EAT study suggests that there might be 
an interaction between FLG and water hardness.8 We will 
examine the relationship between FLG mutation status 
and risk of eczema in a subgroup analysis and explore 
the relationship between FLG mutation status and skin 
microbiome diversity, TEWL and cutaneous cytokine 
expression. DNA will be extracted by standard techniques 
and FLG whole gene sequencing will be used for geno-
typing FLG loss-of-function sequence variants and the 
presence of intragenic copy number variations (Wong 
et al JACI, 2017). Buccal swab for DNA will be collected 
once, during the 4-week visit if consent is given. If unable 
to collect at the 4-week visit, collection will be attempted 
at 3-month visit or 6-month visit.
We will sample the antecubital fossa and the cheek using 
Isohelix bacterial DNA swabs (Cell Projects, Harrietsham, 
UK). A further swab will be taken from each nostril using 
an Ultra Minitip Flocked Swab (Copan Flock Technolo-
gies, Brescia, Italy). A control sample is taken for each 
participant. We will use Illumina MiSeq V1–V3 Amplicon 
sequencing of the 16S ribosomal subunit to characterise 
both skin and nasal bacteria communities with regard 
to species diversity. We will examine within-participant 
changes in microbial diversity over time and explore the 
relationship between water hardness, microbial diversity 
and FLG gene mutational profile as well as taking into 
account environmental factors such as mode of delivery 
and antibiotic use in the mother and infant.
Statistical analysis
The feasibility parameters of this pilot trial will not be 
formally statistically tested. The focus will therefore be on 
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descriptive statistics and CIs. A separate and full SAP for the 
feasibly trial and analysis of mechanistic data will be devel-
oped prior to unblinding and any analysis of the data.
Randomisation will be in a 1:1 ratio using randomly 
permuted blocks. Participants’ data will be analysed on 
an intention-to-treat basis. There will be no hypothesis 
testing for the clinical outcomes except in relation to the 
embedded mechanistic study. Results will be presented as 
estimates with 95% CIs, where appropriate.
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